Table 5

Non-statin based trials in subjects with coronary heart disease: trials with clinical CHD end points

		Lipid lowering (% change)
	Treatment	Chol	Trig	HDL	Reduction in CHD end point
Baseline mean cholesterol 4.5–6.5 mmol/l.
Coronary Drug Project (1975)^w33	Nicotinic acid	−10	−26		↓23%
	Clofibrate	−7	−22		↓23%

Stockholm Ischaemic Heart Disease Secondary Prevention Study (1988)^w34	Clofibrate + nicotinic acid	−13	−19		↓36%

Veterans Affairs Cooperative Studies Program: High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) (1999)^w35	Gemfibrozil	−4	−31	+6	↓22%

Bezafibrate Infarction Prevention (BIP) Study (2000)^w36	Bezafibrate	−4	−21	+18	NS (↓40% only in Trig >2.3)